| scholarly article | Q13442814 |
| P50 | author | Shane V Hegarty | Q57158365 |
| Aideen M Sullivan | Q64680934 | ||
| Amnah M Alshangiti | Q92309379 | ||
| Gerard O'Keeffe | Q42760916 | ||
| P2093 | author name string | Eszter Tuboly | |
| Cathal M McCarthy | |||
| P2860 | cites work | Epidemiology of childhood cancer | Q22252247 |
| High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma | Q24200296 | ||
| Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study | Q24658339 | ||
| Molecular targeted approaches to cancer therapy and prevention using chalcones | Q27021479 | ||
| Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies | Q28080842 | ||
| Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 | ||
| Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells | Q31512518 | ||
| Isobavachalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma | Q33301634 | ||
| The prenatal origins of cancer | Q33697463 | ||
| Flavonoids: an overview | Q33782251 | ||
| Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group | Q33876841 | ||
| Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy | Q34159386 | ||
| Natural products: an evolving role in future drug discovery. | Q34213315 | ||
| Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes | Q34257086 | ||
| Cancer's molecular sweet tooth and the Warburg effect. | Q34566915 | ||
| Pharmacologic management of high-risk neuroblastoma in children | Q35064095 | ||
| Mitochondrial recoupling: a novel therapeutic strategy for cancer? | Q35208039 | ||
| Neuroblastoma: developmental biology, cancer genomics and immunotherapy | Q35283020 | ||
| Transcriptional regulation and transformation by Myc proteins | Q36215755 | ||
| Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo | Q36291188 | ||
| Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management | Q36747677 | ||
| In silico identification of anti-cancer compounds and plants from traditional Chinese medicine database. | Q36870882 | ||
| Chalcones as potent tyrosinase inhibitors: the effect of hydroxyl positions and numbers | Q44961682 | ||
| Inhibition of hydrogen peroxide-induced necrotic cell death with 3-amino-2-indolylmaleimide derivatives | Q46476242 | ||
| Childhood cancer incidence and survival in Japan and England: A population-based study (1993-2010). | Q47409538 | ||
| Uncoupling Effect of F16 Is Responsible for Its Mitochondrial Toxicity and Anticancer Activity | Q47600715 | ||
| MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling. | Q49647074 | ||
| Origin and initiation mechanisms of neuroblastoma | Q49993961 | ||
| Effect of mitochondrial uncouplers niclosamide ethanolamine (NEN) and oxyclozanide on hepatic metastasis of colon cancer. | Q50025648 | ||
| MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. | Q52694952 | ||
| Phloretin-induced apoptosis in B16 melanoma 4A5 cells and HL60 human leukemia cells. | Q53703368 | ||
| Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms. | Q53706753 | ||
| Neuroblastoma | Q54265665 | ||
| Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone. | Q54502733 | ||
| MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma. | Q55319096 | ||
| Mito-TEMPO improves development competence by reducing superoxide in preimplantation porcine embryos. | Q55689115 | ||
| Recent advances in neuroblastoma | Q56637924 | ||
| High-Risk Neuroblastoma Treatment Review | Q57167141 | ||
| Glutathione Transferases: Potential Targets to Overcome Chemoresistance in Solid Tumors | Q60932204 | ||
| PRIMA-1-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level | Q64239929 | ||
| Effect of synthetic and naturally occurring chalcones on ovarian cancer cell growth: structure-activity relationships | Q71781930 | ||
| Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method | Q80093433 | ||
| Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease | Q80249401 | ||
| Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study | Q80304240 | ||
| Neuroblastoma | Q88730901 | ||
| Glutathione metabolism in cancer progression and treatment resistance | Q89143437 | ||
| MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification | Q89748900 | ||
| In vitro selective cytotoxicity of the dietary chalcone cardamonin (CD) on melanoma compared to healthy cells is mediated by apoptosis | Q90280331 | ||
| Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy | Q91247450 | ||
| Cytotoxic effects of 4'-hydroxychalcone on human neuroblastoma cells (SH-SY5Y) | Q93166412 | ||
| High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma | Q36893712 | ||
| Glutathione in cancer cell death | Q37129883 | ||
| Neuroblastoma and MYCN | Q37201479 | ||
| MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. | Q37257626 | ||
| Role of uncoupling proteins in cancer | Q37328314 | ||
| Flavonoid-induced glutathione depletion: potential implications for cancer treatment | Q37698424 | ||
| Natural products for cancer chemotherapy | Q37849845 | ||
| Development of treatment strategies for advanced neuroblastoma | Q38010377 | ||
| Pro-oxidant natural products as anticancer agents. | Q38010738 | ||
| Oxidative stress and cancer: an overview | Q38057533 | ||
| Antitumor properties of natural compounds and related molecules. | Q38060199 | ||
| A Review on Mechanisms of Anti Tumor Activity of Chalcones | Q38484702 | ||
| Anti-cancer chalcones: Structural and molecular target perspectives | Q38501283 | ||
| Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group | Q38684328 | ||
| In vitro and in vivo anticancer studies of 2'-hydroxy chalcone derivatives exhibit apoptosis in colon cancer cells by HDAC inhibition and cell cycle arrest | Q38685191 | ||
| A novel chalcone derivative S17 induces apoptosis through ROS dependent DR5 up-regulation in gastric cancer cells | Q38693854 | ||
| Anti-cancer activity of trans-chalcone in osteosarcoma: Involvement of Sp1 and p53. | Q38842140 | ||
| Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f | Q38964665 | ||
| Design, synthesis and cytotoxic activities of novel aliphatic amino-substituted flavonoids. | Q39063075 | ||
| Mitochondrial uncoupling in cancer cells: Liabilities and opportunities. | Q39088758 | ||
| Apoptotic events induced by synthetic naphthylchalcones in human acute leukemia cell lines | Q39222779 | ||
| Chalcone: A Privileged Structure in Medicinal Chemistry | Q39295083 | ||
| The aromatic ketone 4'-hydroxychalcone inhibits TNFα-induced NF-κB activation via proteasome inhibition | Q39518565 | ||
| 4′-Acetoamido-4-hydroxychalcone, a chalcone derivative, inhibits glioma growth and invasion through regulation of the tropomyosin 1 gene | Q39640704 | ||
| Fluorinated 2'-hydroxychalcones as garcinol analogs with enhanced antioxidant and anticancer activities | Q39664809 | ||
| Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase | Q39735759 | ||
| Hydroxychalcones induce apoptosis in B16-F10 melanoma cells via GSH and ATP depletion. | Q39884933 | ||
| Studies of structure-activity relationship on plant polyphenol-induced suppression of human liver cancer cells | Q39944192 | ||
| Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships | Q40154788 | ||
| N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. | Q40933088 | ||
| Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells. | Q41084306 | ||
| Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells | Q41458947 | ||
| Oxidative phosphorylation is impaired by prolonged hypoxia in breast and possibly in cervix carcinoma | Q42960308 | ||
| Glutathione is key to the synergistic enhancement of doxorubicin and etoposide by polyphenols in leukaemia cell lines. | Q43076940 | ||
| Activation of oxidative stress response by hydroxyl substituted chalcones and cyclic chalcone analogues in mitochondria. | Q43224778 | ||
| Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities | Q43929977 | ||
| Molecular cytotoxic mechanisms of anticancer hydroxychalcones | Q44956291 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P921 | main subject | neuroblastoma | Q938205 |
| P304 | page(s) | 1670759 | |
| P577 | publication date | 2019-12-05 | |
| P1433 | published in | Oxidative medicine and cellular longevity | Q26840015 |
| P1476 | title | 4-Hydroxychalcone Induces Cell Death via Oxidative Stress in MYCN-Amplified Human Neuroblastoma Cells | |
| P478 | volume | 2019 |
Search more.